全文获取类型
收费全文 | 32507篇 |
免费 | 2839篇 |
国内免费 | 996篇 |
专业分类
耳鼻咽喉 | 224篇 |
儿科学 | 787篇 |
妇产科学 | 181篇 |
基础医学 | 3506篇 |
口腔科学 | 396篇 |
临床医学 | 3745篇 |
内科学 | 3197篇 |
皮肤病学 | 257篇 |
神经病学 | 1873篇 |
特种医学 | 1875篇 |
外国民族医学 | 1篇 |
外科学 | 6398篇 |
综合类 | 4350篇 |
预防医学 | 2813篇 |
眼科学 | 1599篇 |
药学 | 2653篇 |
11篇 | |
中国医学 | 1197篇 |
肿瘤学 | 1279篇 |
出版年
2023年 | 616篇 |
2022年 | 759篇 |
2021年 | 972篇 |
2020年 | 890篇 |
2019年 | 841篇 |
2018年 | 1062篇 |
2017年 | 772篇 |
2016年 | 1138篇 |
2015年 | 1477篇 |
2014年 | 2103篇 |
2013年 | 2134篇 |
2012年 | 1787篇 |
2011年 | 1628篇 |
2010年 | 1500篇 |
2009年 | 1622篇 |
2008年 | 1562篇 |
2007年 | 1360篇 |
2006年 | 1223篇 |
2005年 | 1194篇 |
2004年 | 1323篇 |
2003年 | 810篇 |
2002年 | 619篇 |
2001年 | 631篇 |
2000年 | 517篇 |
1999年 | 449篇 |
1998年 | 515篇 |
1997年 | 562篇 |
1996年 | 532篇 |
1995年 | 517篇 |
1994年 | 636篇 |
1993年 | 434篇 |
1992年 | 522篇 |
1991年 | 452篇 |
1990年 | 419篇 |
1989年 | 335篇 |
1988年 | 392篇 |
1987年 | 215篇 |
1986年 | 214篇 |
1985年 | 228篇 |
1984年 | 203篇 |
1983年 | 115篇 |
1982年 | 203篇 |
1981年 | 158篇 |
1980年 | 143篇 |
1979年 | 107篇 |
1978年 | 92篇 |
1977年 | 82篇 |
1976年 | 63篇 |
1975年 | 46篇 |
1973年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
2.
3.
4.
《Journal of vascular and interventional radiology : JVIR》2022,33(10):1143-1150
PurposeTo report the 5-year results from the Pivotal Multicenter Trial of Ultrasound-Guided Percutaneous Arteriovenous Fistula (pAVF) Creation for Hemodialysis Access.Materials and MethodsThe retrospective review of 107 intent-to-treat (ITT) patients from the pivotal trial provided a long-term follow-up population (LTP) of 85 patients with a median follow-up duration of 50 months (range, 12–60 months). Data evaluated in the LTP group were fistula maturation and usage, secondary procedures, and complications. The Kaplan-Meier analysis of primary patency, assisted primary patency, cumulative patency, and functional patency (time from 2-needle cannulation to abandonment) were performed for the ITT population.ResultsIn the LTP, 99% (84 of 85) of fistulae were mature, with 99% (78 of 79) of patients requiring hemodialysis using their pAVF. Sustained fistula use (2-needle cannulation at the prescribed rate, 2 of 3 sessions) was achieved in 92% (78 of 85) of patients, with 7 patients not using their pAVF because they were not on dialysis (n = 4), were on peritoneal dialysis (n = 2), and refused to use fistula (n = 1). Fistula maintenance was required in 31.8% (27 of 85) of patients and included fistula dysfunction (21.2%), thrombosis (5.9%), cannulation injury (12.9%), and arm swelling (4.7%). The number of procedures performed per patient per year to maintain function and patency was 0.32 (91 of 288) for years 2–5. The cumulative patency rates were 89.5%, 88.4%, 88.4%, 85.6%, and 82.0% for years 1, 2, 3, 4, and 5, respectively. The functional patency was 91.8% at the end of the study. There were no major complications related to pAVF during the long-term follow-up.ConclusionsPercutaneous fistulae have provided clinically effective and durable access for hemodialysis with low complications. The continued use and evaluation of pAVF are warranted. 相似文献
5.
6.
采用Mimics对心脏进行三维重构,用3-matic进行模型优化以及模型误差分析,对左心室室壁运动做速度分布假设,基于UDF宏文件对左心室室壁运动编写程序,将血液视为非牛顿流体,采用动网格技术研究不同血压对左心室血液流动的影响。模拟发现当左心室收缩时,压力梯度明显,内部压力减小。当左心室舒张时,内部压力逐渐增高。二尖瓣口处的速率先增大后减小。血压升高,左心室内剪切应力持续增大,极易破坏红细胞结构,产生溶血现象,导致心脏功能紊乱。 相似文献
7.
8.
9.
10.